09:50 AM EDT, 03/09/2026 (MT Newswires) -- AbbVie ( ABBV ) said Monday that topline results from the multiple ascending dose part of its phase 1 study of subcutaneous ABBV-295 to treat for chronic weight management showed the drug significantly outperformed placebo.

The company said ABBV-295 demonstrated clinically meaningful, dose-dependent reductions in body weight over a 12-13-week period. It said the mean percentage change in body weight ranged from approximately 7.8% to 9.8% at week 12 for groups receiving does every week.

AbbVie ( ABBV ) also reported weight loss of approximately 7.9% to 9.7% at week 13 for the group that was dosed every other week.

These were compared with a mean weight loss of 0.26% and 0.25% in the placebo group at week 12 and week 13, respectively, the company said.

Price: 229.13, Change: -0.95, Percent Change: -0.41